tirzepatide for alcohol use disorder attenuates dopamine reward signaling and suppresses drinking and relapse-like behaviors in rodents Semaglutide and tirzepatide decrease cravings

Initiate appropriate supportive treatment according to the patient's clinical signs and symptoms

After 4 weeks, increase to 5 mg once weekly

Tirzepatide is a dual GLP-1/GIP receptor agonist

However, peptides of the gut-brain axis appear to offer promising therapeutic targets for AUD as they influence the mesolimbic reward circuitry

Older adults may experience slower overall weight loss due to reduced metabolic rate and lean muscle mass

The dual agonist mechanism provides robust glycemic control and significant weight reduction, with clinical trials demonstrating A1C reductions of 1.92.4% and weight loss of approximately 1522% of body weight in non-diabetic adults with obesity (SURMOUNT-1 trial), with more modest weight loss typically observed in patients with type 2 diabetes